doi:

DOI: 10.3724/SP.J.1008.2015.01277

Academic Journal of Second Military Medical University (第二军医大学学报) 2015/36:12 PP.1277-1283

Preparation and in vitro evaluation of pancreatic cancer-targeted nano-scale ultrasound contrast agent


Abstract:
Objective To prepare a pancreatic cancer-targeted nano-scale ultrasound contrast agent (T-UCA) and to evaluate its in vitro targeting effect. Methods PLGA-PEG-NHS was synthesized with poly(lactic-co-glycolic acid) (PLGA), N-hydroxysuccinimide (NHS) and polyethylene glycol (PEG). The construction of PLGA-PEG-NHS was characterized by 1H-NMR. Perfluoroctyl bromide (PFOB)-loaded PLGA nanoparticle contrast agent was prepared using emulsion evaporation technique with PLGA-PEG-NHS and PFOB, and the products were further conjugated with Hedgehog antibody. The morphology of T-UCA were characterized by transmission electron microscopy, and the size distribution and Zeta potential of T-UCA were characterized by dynamic light scattering method. Furthermore, the drug entrapment efficiency and loading capacity of T-UCA were determined by GC-MS,and the release rate of T-UCA in vitro was examined by dialysis method. Finally, the in vitro targeting performance was quantitatively verified by fluorescence microscopy and flow cytometry with human pancreatic cancer lines SW1990 and CFPAC-1. Results The average diameter and the Zeta potential of T-UCA were 198.9 nm and -31.8 mV, respectively. Moreover, the encapsulation efficiency and drug loading of T-UCA was (63.7 ± 3.9)% and (14.3 ± 0.9)%, respectively. Nearly 85.3% liquid perfluorocarbon was released from the T-UCA within 48 h. In vitro cell experiments showed that the targeted contrast agent could bind to SW1990 cells which had high expression of Hedgehog antigen, while not to the CFPAC-1 cells without expression of Hedgehog antigen. Conclusion The emulsion evaporation technique can be used to prepare T-UCA with desirable characteristics, and the prepared T-UCA can specifically target the pancreatic cancer cells with high expression of Hedgehog, making it a promising pancreatic cancer-targeted nanosacle ultrasound contrast agent.

Key words:nano-scale ultrasound contrast agent;pancreatic neoplasms;targeting therapy;polylactic-co-glycolic acid;perfluoroctyl bromide

ReleaseDate:2016-05-27 09:19:59



[1] Hidalgo M. Pancreatic cancer [J]. N Engl J Med, 2010, 362: 1605-1617.

[2] Verbeke C S. Resection margins in pancreatic cancer[J]. Pathologe, 2013, 34(Suppl 2): 241-247.

[3] Bilimoria K Y, Bentrem D J, Feinglass J M, Stewart A K, Winchester D P, Talamonti M S, et al. Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery [J]. J Clin Oncol, 2008, 26: 4626-4633.

[4] Diethich C F, Sharma M, Hocke M. Contrast-enhanced endoscopic ultrasound [J]. Endosc Ultrasound, 2012, 1: 130-136.

[5] Luz L P, Al-Haddad M A, Sey M S, DeWitt J M. Applications of endoscopic ultrasound in pancreatic cancer [J]. World J Gastropenterol, 2014, 20: 7808-7818.

[6] Deshpande N, Needles A, Willmann J K. Molecular ultrasound imaging: current status and future directions [J]. Clin Radiol, 2010, 65: 567-581.

[7] Liu H L, Fan C H, Ting C Y, Yeh C K. Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview [J]. Thernostics, 2014, 4: 432-444.

[8] Kaufmann B A, Lindner J R. Molecular imaging with targeted contrast ultrasound [J]. Curr Opin Biotechnol, 2007, 18: 11-16.

[9] Chiu J W, Wong H, Leung R, Pang R, Cheung T T, Fan S T, et al. Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy [J]. Oncologist, 2014, 19: 937-950.

[10] Gonnissen A, Isebaert S, Haustermans K. Hedgehog signaling in prostate cancer and its therapeutic implication [J]. Int J Mol Sci, 2013, 14:13979-14007.

[11] Choi J S, Seo K, Yoo J W. Recent advances in PLGA particulate systems for drug delivery [J]. J Pharm Invest, 2012, 42: 155-163.

[12] Danhier F, Ansorena E, Silva J M, Coco R, Breton A L, Préat V. PLGA-based nanoparticles: an overview of biomedical applications [J]. J Control Release, 2012, 161: 505-522.

[13] Gao W, Wang J. Synthetic micro/nanomotors in drug delivery [J]. Nanoscale, 2014, 6:10486-10494.

[14] Díaz-López R, Tsapis N, Santin M, Bridal S L, Nicolas V, Jaillard D, et al. The performance of PEGylated nanocapsules of perfluorooctyl bromide as an ultrasound contrast agent [J]. Biomaterials, 2010, 31: 1723-1731.

[15] Díaz-López R, Tsapis N, Fattal E. Liquid perfluorocarbons as contrast agents for ultrasonography and 19F-MRI [J]. Pharm Res, 2010, 27: 1-16.

[16] Zheng S G, Xu H X, Chen H R. Nano/microparticles and ultrasound contrast agents[J]. World J Radiol, 2013, 5: 468-471.

[17] Paefgen V, Doleschel D, Kiessling F. Evolution of contrast agents for ultrasound imaging and ultrasound-mediated drug delivery [J]. Front Pharmacol, 2015, 6:197.

[18] Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A. PEG-a versatile conjugating ligand for drugs and drug delivery systems [J]. J Control Release, 2014, 192: 67-81.

[19] Nichols J W, Bae Y H. EPR: evidence and fallacy [J]. J Control Release, 2014, 190:451-464.

[20] Elzoqhby A O. Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research [J]. J Control Release, 2013, 172: 1075-1091.